This study allows us to further expand our product claims into the sports nutrition marketplace
A first of its kind study published in Nutrients titled, The Effect of Orally Dosed Levagen+ (Palmitoylethanolamide) on Exercise Recovery in Healthy Males, shows that Gencor’s unique extract of Palmitoylethanolamide (PEA), known as Levagen+, may aid in muscle recovery.
PEA has been clinically validated to help with a healthy inflammatory response, reduction of aches and discomforts as well as support joint health, stiffness and function. This newly published study utilized Gencor’s Levagen+, which is Levagen powered by LipiSperse dispersion technology, to examine its efficacy on recovery from muscle-damaging exercise.
"We are thrilled with the results of this study which further verifies the potent effects of Levagen+ and validates PEA's ability to help with muscle recovery," said Chase Shryoc, VP of Sales and Business Development at Gencor. "This study allows us to further expand our product claims into the sports nutrition marketplace."
The double-blind, randomised, placebo-controlled study consisted of 28 healthy males who consumed either Levagen+ or a placebo pre-exercise, post exercise on day one and then 24- and 48-hours post, with a blood draw at the 3-hour mark. The results found that Levagen+ was able to reduce myoglobin, a marker of skeletal muscle damage, and increase protein kinase B phosphorylation following exercise. This indicates that PEA supplementation can aid in muscle recovery from repeat bouts of exercise.
"This clinical shows us that Levagen+ may allow individuals to exercise at a higher intensity for longer," said Maggie McNamara, Marketing Manager at Gencor. "Levagen+ is for the consumer looking to take their workouts to the next level, and due to Levagen+'s versatility, it can be applied in tablets, capsules, and functional foods and beverages, including RTD, sachets, smoothies, chocolate and more."